A Phase IIb, Randomised, Multicentre, Double-Blind Study to Evaluate the Effect of Baxdrostat in Combination with Dapagliflozin Compared with Baxdrostat on Albuminuria in Participants with Chronic Kidney Disease and High Blood Pressure

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-522407-23-00

Enrollment

Registered

2026-02-16

Start date

Unknown

Completion date

Unknown

Last updated

2026-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease (CKD) and hypertension.

Brief summary

Change from baseline in UACR at Week 12

Interventions

DRUGDapagliflozin Placebo

DRUGForxiga 10 mg film-coated tablets

DRUGBaxdrostat

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Change from baseline in UACR at Week 12	—

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 17, 2026